Cyclacel Pharmaceuticals Inc (NASDAQ:CYCC) Short Interest Down 21.1% in September

Cyclacel Pharmaceuticals Inc (NASDAQ:CYCC) saw a significant decline in short interest in the month of September. As of September 30th, there was short interest totalling 324,800 shares, a decline of 21.1% from the August 30th total of 411,600 shares. Based on an average trading volume of 73,200 shares, the days-to-cover ratio is currently 4.4 days. Approximately 1.9% of the company’s shares are sold short.

An institutional investor recently raised its position in Cyclacel Pharmaceuticals stock. Renaissance Technologies LLC boosted its holdings in Cyclacel Pharmaceuticals Inc (NASDAQ:CYCC) by 82.5% in the second quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 1,102,400 shares of the biotechnology company’s stock after purchasing an additional 498,200 shares during the quarter. Renaissance Technologies LLC owned about 6.41% of Cyclacel Pharmaceuticals worth $596,000 at the end of the most recent quarter. 8.96% of the stock is currently owned by institutional investors.

Shares of Cyclacel Pharmaceuticals stock traded up $0.02 during midday trading on Friday, reaching $0.38. The company had a trading volume of 10,994 shares, compared to its average volume of 57,694. The stock has a fifty day moving average price of $0.41 and a 200 day moving average price of $0.58. The company has a debt-to-equity ratio of 0.08, a current ratio of 7.26 and a quick ratio of 7.26. The firm has a market cap of $6.23 million, a PE ratio of -0.61 and a beta of 3.02. Cyclacel Pharmaceuticals has a fifty-two week low of $0.28 and a fifty-two week high of $1.70.

Cyclacel Pharmaceuticals (NASDAQ:CYCC) last issued its earnings results on Tuesday, August 13th. The biotechnology company reported ($0.16) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.15) by ($0.01). As a group, sell-side analysts forecast that Cyclacel Pharmaceuticals will post -0.62 EPS for the current year.

Separately, Zacks Investment Research lowered Cyclacel Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Friday, August 16th.

Cyclacel Pharmaceuticals Company Profile

Cyclacel Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's oncology development programs include CYC065, a cyclin dependent kinase Inhibitors (CDK) that is in Phase I clinical trial for the treatment of solid tumors, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and CYC140, a polo-like kinase inhibitor program, which is in Phase I clinical trial for the treatment of advanced leukemias.

Recommended Story: What can cause a stock to outperform?

Receive News & Ratings for Cyclacel Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cyclacel Pharmaceuticals and related companies with's FREE daily email newsletter.